442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
Abstract
Colorectal cancer (CRC) is among the highest incidence and mortality cancer rates. Immune check-point blockade (ICB) showed clinical benefit in patients (pts) in MSI metastatic CRC (mCRC) but not in MSS pts. Cancer vaccines with autologous dendritic cells (ADC) could be a complementary therapeutic approach to ICB with potentially synergistic...
Paper Details
Title
442P A phase I-II multicenter trial with avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients. GEMCAD 16-02 (AVEVAC trial)
Published Date
Sep 1, 2021
Journal
Volume
32
Pages
S555 - S555
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History